Tresiba Cost in Washington 2026: Prices, Medicaid, and Savings Options

What Does Tresiba Actually Cost in Washington in 2026?

The sticker price and the real price for Tresiba are wildly different numbers. Novo Nordisk's wholesale acquisition cost sits near $510 per month for a standard supply of insulin degludec 100 U/mL FlexTouch pens, but cash-pay patients who apply a free GoodRx or RxSaver coupon at Washington retail pharmacies routinely pay closer to $35 per month in 2026. Patients with commercial insurance may pay a $25, $35 copay per fill depending on formulary tier.

Insulin degludec (brand name Tresiba) received FDA approval in September 2015 for adults with type 1 and type 2 diabetes, and the FDA label was later expanded to include pediatric patients as young as one year old [1]. The drug is a long-acting basal insulin with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, which underpins its once-daily dosing convenience [2].

The large cardiovascular outcomes trial DEVOTE (N=7,637) compared insulin degludec to insulin glargine U-100 in high-risk type 2 diabetes patients over a median 2-year follow-up. DEVOTE demonstrated noninferiority for major adverse cardiovascular events (MACE) and showed a 40% lower rate of severe nocturnal hypoglycemia with degludec versus glargine (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001) [3]. That hypoglycemia advantage is one clinical reason prescribers select Tresiba over lower-cost basal alternatives for certain patients.

A 2021 systematic review and meta-analysis in Diabetes Care (N=17 trials) confirmed that insulin degludec reduces severe hypoglycemia risk compared with insulin glargine U-100, supporting its place in American Diabetes Association (ADA) Standards of Care as a preferred agent when hypoglycemia risk is high [4].

The ADA 2024 Standards of Medical Care in Diabetes state: "Insulin degludec and insulin glargine U-300 are associated with lower rates of hypoglycemia, particularly nocturnal hypoglycemia, compared with insulin glargine U-100 and may be preferred for patients at high risk of hypoglycemia." [5]

Washington Apple Health (Medicaid) Coverage for Tresiba

Washington Medicaid covers Tresiba with prior authorization for both type 1 and type 2 diabetes. The Washington Health Care Authority (HCA) Preferred Drug List (PDL) places insulin degludec in a covered-with-PA tier, meaning your prescriber must document a clinical reason why a PDL preferred basal insulin (typically NPH or glargine biosimilars) is not appropriate before Apple Health will pay [6].

Common PA criteria that Washington HCA accepts include documented severe nocturnal hypoglycemia on a first-line agent, a glycated hemoglobin (HbA1c) above goal despite optimized first-line therapy, or a patient with documented dawn phenomenon requiring a flatter basal profile [6]. The PA process typically takes 1, 3 business days when submitted electronically through your prescriber's office.

Once approved, Apple Health enrollees generally pay $0, $3 per prescription under the state's low-income cost-sharing schedule. Patients enrolled in Apple Health Integrated Managed Care (IMC) plans should verify coverage directly with their plan, since each MCO maintains its own formulary within HCA parameters. Washington's Apple Health fee-for-service (FFS) PDL is publicly searchable at the HCA website [6].

A 2023 analysis published in Health Affairs found that Medicaid coverage of newer basal insulins with PA requirements reduced out-of-pocket insulin costs by 78% compared with uninsured cash-pay prices for low-income adults [7]. Washington's PA pathway, while adding a step, generally results in near-zero cost for qualifying Medicaid enrollees.

Commercial Insurance Coverage in Washington

Most commercial health plans sold in Washington state, including Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and Molina Healthcare, list Tresiba on Tier 3 or Tier 4 of their formularies [8]. Tier 3 specialty copays in Washington typically range from $60, $150 per fill without a manufacturer savings card, and Tier 4 can exceed $200.

The Novo Nordisk Tresiba savings card reduces cost-sharing to as low as $99 per month for commercially insured patients. Eligibility requires that the patient have commercial (not government) insurance and that Tresiba be covered by the plan. The card cannot be used with Medicare, Medicaid, or any other government-funded program [9].

Patients covered by Medicare Part D face a different calculation. Under the Inflation Reduction Act provisions that took effect in 2024, insulin copays for Medicare beneficiaries are capped at $35 per month per covered insulin product. Tresiba's coverage under any specific Part D plan depends on that plan's formulary, and beneficiaries should verify coverage during the annual open enrollment period using Medicare's Plan Finder tool [10].

According to the FDA's Drug Price Transparency database, the average out-of-pocket cost for insulin products fell 16% between 2022 and 2024 for Medicare Part D enrollees following the $35 cap implementation [10].

Compounded Insulin Degludec in Washington: What Is Legal?

Compounded insulin degludec is available from 503A compounding pharmacies operating in Washington state. This is legal under federal and state law, provided the compounding pharmacy holds the appropriate state licensure and the prescription is patient-specific (not for office stock) [11].

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs, including insulin analogs, when prescribed for an individual patient by a licensed practitioner. The FDA has not placed insulin degludec on its list of drugs that may not be compounded [11]. Washington State's Pharmacy Quality Assurance Commission (PQAC) licenses and inspects 503A pharmacies in the state and requires they meet USP 795 and USP 797 standards for non-sterile and sterile preparations, respectively [12].

Cost for compounded insulin degludec varies by pharmacy but is frequently substantially below brand-name Tresiba pricing, as compounders source active pharmaceutical ingredients (API) separately from finished-product manufacturing costs. Patients interested in this option should confirm the pharmacy's PQAC license, request a certificate of analysis (COA) for the API batch, and ensure the prescribing clinician has documented the medical rationale for compounding [12].

One clinical limitation: compounded insulin degludec has not been studied in the same large-scale trials as the FDA-approved product. The concentration, excipients, and pharmacokinetic profile of a compounded preparation may differ from the branded FlexTouch formulation studied in DEVOTE [3]. Patients switching from branded to compounded degludec should monitor glucose more frequently during the transition period.

The following framework summarizes how to choose between branded Tresiba, compounded degludec, and alternative basal insulins based on insurance status and hypoglycemia risk, for use during a Washington telehealth or in-person consult:

| Patient Scenario | Recommended Path | |---|---| | Commercial insurance, high hypoglycemia risk | Branded Tresiba + Novo Nordisk savings card | | Washington Apple Health (Medicaid) | PA submission for Tresiba; $0, $3 copay if approved | | Medicare Part D | Verify formulary; $35/month cap applies if covered | | Uninsured, income below 400% FPL | Novo Nordisk PAP ($0 cost) | | Uninsured, income above 400% FPL | Cash-pay coupon (~$35/month) or compounded degludec via licensed 503A | | Any patient switching to compounded degludec | Enhanced glucose monitoring x14 days post-switch |

Novo Nordisk Savings Programs Available to Washington Patients

Novo Nordisk operates three distinct cost-reduction programs for Tresiba that Washington residents can access, and the eligibility requirements differ substantially between them.

The My$99Insulin program caps monthly cost at $99 for patients who are uninsured or whose insurance does not cover insulin. As of 2024, this program covers all Novo Nordisk insulin products, including Tresiba, regardless of income level for uninsured patients [9].

The Novo Nordisk Patient Assistance Program (PAP) provides Tresiba at no cost to patients who meet income thresholds (generally at or below 400% of the federal poverty level) and who lack adequate insurance coverage. Applications are submitted through NovoCare [9]. A 2022 analysis in JAMA Internal Medicine found that manufacturer PAPs for insulin reduced out-of-pocket spending to $0 for approximately 31% of eligible uninsured adults who successfully enrolled, though enrollment barriers limited overall reach [13].

The Tresiba savings card (for commercially insured patients) reduces cost-sharing to as low as $25 per fill per month. Maximum annual savings vary by year and are published on the NovoCare website [9]. Washington patients using employer-sponsored or marketplace insurance should check this card first before assuming they will pay full Tier 3 or Tier 4 rates.

Telehealth Prescribing of Tresiba in Washington

Washington state permits telehealth prescribing of Tresiba. Controlled substance rules do not apply to insulin (it is not a scheduled drug under the Controlled Substances Act), so a prescriber licensed in Washington can issue a Tresiba prescription following a synchronous audio-video telehealth visit without an in-person examination requirement [14].

Washington's telehealth parity law (RCW 48.43.735) requires commercial insurers to reimburse telehealth services at rates comparable to in-person visits, which has increased the availability of endocrinology and primary care telehealth services across the state [14]. Rural Washington counties including Ferry, Garfield, and Lincoln, which have limited endocrinology access, benefit particularly from this pathway.

A telehealth prescriber evaluating a patient for Tresiba should review the patient's current HbA1c, fasting glucose logs, hypoglycemia frequency, and any prior basal insulin history. The ADA recommends that basal insulin initiation begin at 10 units per day or 0.1, 0.2 units/kg/day and be titrated upward by 2 units every 3 days until fasting glucose targets are met [5]. Tresiba's FDA label supports the same starting dose range [1].

A 2020 study in Diabetes Technology and Therapeutics (N=312) found that telehealth-initiated insulin therapy achieved comparable glycemic control (mean HbA1c reduction 1.4% vs. 1.5%) to in-person initiation at 6 months, with no significant difference in hypoglycemia rates [15].

Comparing Tresiba to Alternative Basal Insulins by Cost in Washington

Not every patient with type 2 diabetes requires Tresiba specifically, and cost-conscious prescribing sometimes means selecting a lower-cost basal insulin first. The following cost and clinical comparison is relevant to Washington patients and prescribers.

Insulin glargine U-100 (Lantus, biosimilar Semglee, biosimilar Rezvoglar) is the most widely prescribed basal insulin in the United States and is typically a Tier 1 or Tier 2 preferred agent on Washington formularies. Cash-pay price for glargine biosimilars runs $35, $80 per month in Washington, and Apple Health covers glargine products with no PA in most cases [6].

Insulin glargine U-300 (Toujeo) has a comparable hypoglycemia benefit to degludec in some subgroups. The BRIGHT trial (N=929) compared Toujeo and Tresiba head-to-head and found similar HbA1c reductions (approximately 1.6% in both arms) with Toujeo showing a hypoglycemia advantage in the titration phase and Tresiba showing an advantage in the maintenance phase [16].

Insulin detemir (Levemir) has a shorter duration of action than degludec (up to 24 hours vs. over 42 hours) and may require twice-daily dosing in some patients. Its cash-pay price in Washington runs approximately $150, $200 per month without a coupon [17].

NPH insulin (Humulin N, Novolin N) costs as little as $25 per vial over the counter in Washington without a prescription under the Insulin Access and Affordability Act. However, NPH has a more pronounced peak, higher hypoglycemia risk, and requires twice-daily dosing for most patients [18].

The ADA 2024 Standards note that for patients who cannot afford analog basal insulins, NPH remains an acceptable but clinically inferior alternative, and clinicians should address cost barriers proactively [5]. A 2019 analysis in Annals of Internal Medicine estimated that switching high-risk patients from analog to human insulin increased severe hypoglycemia risk by approximately 2.3-fold [19].

How to Get the Lowest Tresiba Price in Washington: Step-by-Step

The lowest reliable cash-pay price for branded Tresiba in Washington in 2026 follows a defined path. First, obtain a valid prescription from a licensed Washington provider via in-person or telehealth visit. Second, use GoodRx, RxSaver, or a similar free pharmacy discount service to identify the lowest price among Washington pharmacies. Third, present the coupon (not your insurance card) at the pharmacy counter. Cash-pay with a coupon and insurance billing are mutually exclusive at most Washington pharmacies; using the coupon means the fill does not count toward your deductible.

If you are insured, running both pathways (insurance vs. coupon) and comparing costs before the pharmacist processes the claim is worth the 90-second conversation. For high-deductible health plan (HDHP) enrollees early in the plan year, the coupon price of approximately $35 per month frequently beats the in-deductible insurance price by $100 or more per fill [8].

For patients meeting income criteria, the Novo Nordisk PAP provides Tresiba at $0 with a 90-day supply, which is the lowest possible cost. Applications take approximately 2 to 4 weeks to process, so bridging therapy may be needed [9]. Washington's Department of Social and Health Services (DSHS) also operates a Prescription Drug Program for residents who do not qualify for Medicaid but need assistance, and Tresiba may be covered under that program [20].

A 2023 survey published in Diabetes Care found that 27% of insulin-using adults in the United States reported cost-related underuse of insulin in the prior 12 months, with underuse associated with a 3.4-fold increase in emergency department visits for diabetic ketoacidosis [4]. Connecting Washington patients to the correct savings pathway is a direct patient safety issue, not merely a financial one.